

REVIEW ARTICLE

Chlamydia psittaci (psittacosis) as a cause of community-acquired pneumonia: a systematic review and meta-analysis

L. HOGERWERF¹*, B. DE GIER¹, B. BAAN^{1,2} AND W. VAN DER HOEK¹

¹ National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Antonie van Leeuwenhoeklaan 9, 3721 MA Bilthoven, the Netherlands

² VU University Amsterdam, Athena Institute, De Boelelaan 1105, 1081 HV Amsterdam, the Netherlands

Received 6 March 2017; Final revision 17 July 2017; Accepted 16 August 2017;
first published online 26 September 2017

SUMMARY

Psittacosis is a zoonotic infectious disease caused by the transmission of the bacterium *Chlamydia psittaci* from birds to humans. Infections in humans mainly present as community-acquired pneumonia (CAP). However, most cases of CAP are treated without diagnostic testing, and the importance of *C. psittaci* infection as a cause of CAP is therefore unclear. In this meta-analysis of published CAP-aetiological studies, we estimate the proportion of CAP caused by *C. psittaci* infection. The databases MEDLINE and Embase were systematically searched for relevant studies published from 1986 onwards. Only studies that consisted of 100 patients or more were included. In total, 57 studies were selected for the meta-analysis. *C. psittaci* was the causative pathogen in 1·03% (95% CI 0·79–1·30) of all CAP cases from the included studies combined, with a range between studies from 0 to 6·7%. For burden of disease estimates, it is a reasonable assumption that 1% of incident cases of CAP are caused by psittacosis.

Key words: Aetiology, *Chlamydia psittaci*, community-acquired pneumonia, psittacosis.

INTRODUCTION

Psittacosis is an infectious disease caused by the bacterium *Chlamydia psittaci*. Human cases of infection can occur via the inhalation of contaminated aerosols originating from urine, faeces, or other excretions from infected birds [1]. Infection with *Chlamydia psittaci* is mainly described in situations that entail close contact with birds. This includes pet shops, veterinary hospitals, and bird shows [2–4]. Furthermore, *C. psittaci* infections are reported in poultry, with human cases linked to occupational exposure in the poultry industry [5–7].

Upon successful transmission to humans, *C. psittaci* mainly presents as a non-specific flu-like illness or ‘community-acquired pneumonia’ (CAP) [1]. However, the proportion of CAP cases caused by *C. psittaci* is unclear. Diagnostic tests for *C. psittaci* are rarely done when patients present with CAP [8]. This is in line with prevailing guidelines for general practitioners and medical specialists in countries such as the USA, the UK, and the Netherlands that microbiological investigation is not necessary for adequate treatment of uncomplicated pneumonia [8]. However, this implies that the individual patient with *C. psittaci* pneumonia might not get the optimal treatment. For example, the common presumptive treatment for CAP in the Netherlands is amoxicillin, which is not effective against *C. psittaci*. In addition, from a public health point of view it is important to trace the source of any human psittacosis case.

* Author for correspondence: L. Hogerwerf, Centre for Infectious Disease Control (CIb), National Institute for Public health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, P.O. Box 1, 3720 BA Bilthoven, the Netherlands.
(Email: lenny.hogerwerf@rivm.nl)




Fig. 1. Selection of publications for the review and meta-analysis.

Linking to animal sources requires both human and animal or environmental polymerase chain reaction (PCR)-based diagnostics with ensuing genotyping of isolates [9], as well as veterinary and epidemiological investigation.

The present study was done in the context of an integrated veterinary-human health project entitled Plat4m-2Bt-psittacosis. Two of the aims of this project are to reduce the diagnostic deficit of psittacosis in humans by implementing a harmonised respiratory diagnostic PCR method in medical microbiological laboratories, and to determine the disease burden from psittacosis in humans. A psittacosis disease burden calculation requires information on the incidence of psittacosis, which is currently not available. The objective of the present review is therefore to assess the contribution of *C. psittaci* in the aetiology of CAP in order to obtain a best possible estimate of the real incidence of psittacosis.

METHODS

The focus of this systematic review and meta-analysis was on CAP-aetiological studies that included laboratory diagnostics for *C. psittaci*. We selected articles

from MEDLINE and Embase in March 2015. The following key terms, and multiple synonyms hereof, were used to build the search strategy: ‘psittacosis’, ‘*Chlamydia psittaci*’, ‘*Chlamydophila psittaci*’, ‘ornithosis’, ‘pneumonia’, ‘community-acquired pneumonia’, ‘incidence’, ‘causative pathogens’. During first screening, studies included were those published from 1986 onwards. In studies before 1986, no distinction was possible between infections caused by *C. psittaci* and *C. pneumoniae*, which has a human-to-human transmission route [10]. A further prerequisite for inclusion was that the research population comprised 100 patients or more. Another prerequisite was that the study had to be written in English, Dutch, German, or Spanish. Exclusion criteria during full text assessment for eligibility were a lack of a full text, not being a CAP-aetiological study, no information on *C. psittaci*, no specification of the *Chlamydia* spp., and not presenting original data. Figure 1 shows the search strategy according to PRISMA guidelines [11]. The three additional publications were identified through fellow researchers. Data were extracted about the size of the study population that was tested for *C. psittaci*, and about the number of *C. psittaci* detections, the diagnostic test used, the location, and year

Table 1. *Details of studies included in the review and meta-analysis*

Year of study	Location	Test used	Study population (N)	n (%) <i>C. psittaci</i> infections	Reference	Comments
1980–1981	Switzerland	CF	1494	29 (1.9)	[13]	
1981–1982	Finland	IF	304	3 (1.0)	[14]	
1982–1983	Sweden	CF	327	1 (0.3)	[15]	Only children <15 years
1982–1983	Britain	CF	453	13 (2.9)	[16]	
1982–1984	Sweden	CF	180	6 (3.3)	[17]	
1983	Saudi Arabia	CF	112	2 (1.8)	[18]	
1983–1984	Spain	CF	405	14 (3.5)	[19]	
1985–1986	Spain	CF	510	1 (0.2)	[20]	
1985–1988	Spain	CF	168	1 (0.6)	[21]	
1986–1987	Finland	IF	136	3 (2.2)	[22]	
1987	Sweden	IF	277	3 (1.1)	[23]	
1987–1988	Australia	CF	267	7 (2.6)	[24]	
1987–1989	Ethiopia	CF	103	4 (3.9)	[25]	
1987–1989	France	CF	132	1 (0.8)	[26]	
1987–1995	Spain	CF	416	1 (0.2)	[27]	
1989–1990	Japan	IF	139	0 (0)	[28]	Only children <15 years
1990–1992	Australia	IF	280	0 (0)	[29]	Only children <5 years
1990–1993	Nordic countries	IF	383	4 (1)	[30]	
1991	Papua New Guinea	CF	131	0 (0)	[31]	
1991	Saudi Arabia	CF	341	1 (0.3)	[32]	
1991–1992	Italy	CF	179	12 (6.7)	[33]	
1991–1994	Canada	IF	149	2 (1.3)	[34]	
1992	Spain	IF	165	2 (1.2)	[35]	
1992	Britain	CF, ELISA	275	4 (1.5)	[36]	
1992	Croatia	CF	581	16 (2.8)	[37]	
1992–1994	France	IF	104	1 (1)	[38]	Only children <13 years
1994–1997	Japan	CF	326	7 (2.1)	[39]	
1995–1997	Spain	IF	533	5 (0.9)	[40]	
1995–2000	Réunion	IF	112	0 (0)	[41]	Only patients in intensive care
1995–2001	Spain	IF	1474	16 (1.1)	[42]	
1995–2005	Spain	IF	1556	17 (1.1)	[43]	
1996–1997	Spain	Serology not specified	395	2 (0.5)	[44]	
1996–1997	Slovenia	CF	211	2 (0.9)	[45]	
1996–1997	England	PCR	244	1 (0.4)	[46]	
1996–1999	Spain	IF	221	4 (1.8)	[47]	
1997–1998	Argentina	IF	346	1 (0.3)	[48]	
1997–2000	Spain	IF	247	3 (1.2)	[49]	
1999–2000	Japan	IF	232	5 (2.2)	[50]	
1999–2001	Slovenia	IF	109	1 (0.9)	[51]	
1999–2001	Spain	IF	493	9 (1.8)	[52]	
1999–2002	Sweden	IF	235	3 (1.3)	[53]	
2000–2001	6 countries in Eastern Europe	IF	180	3 (1.7)	[54]	
2000–2004	Spain	CF	911	4 (0.4)	[55]	
2001–2002	Korea	IF	126	0 (0)	[56]	
2001–2004	Japan	CF	349	1 (0.3)	[57]	
2002	Spain	Serology not specified	204	1 (0.5)	[58]	

Table 1 (cont.)

Year of study	Location	Test used	Study population (N)	n (%) <i>C. psittaci</i> infections	Reference	Comments
2002–2011	Japan	Serology not specified	1032	15 (1.5)	[59]	
2003–2005	Chile	IF	176	0 (0)	[60]	
2004–2006	Australia	IF, ELISA	885	2 (0.2)	[61]	
2005–2009	Pan-European	Not specified	1166	10 (0.9)	[62]	Only patients in intensive care
2005–2011	Japan	Culture, IF	786	5 (0.6)	[63]	
2006	Turkey	IF	100	1 (1)	[64]	Only children <12 years
2006–2007	Spain	IF	663	2 (0.3)	[65]	
2007–2010	Netherlands	PCR, CF, IF	147	7 (4.8)	[66]	
2007–2010	Netherlands	Serology not specified	339	3 (0.9)	[67]	
2008–2009	Netherlands	PCR, CF	408	7 (1.7)	[68]	
2011–2012	Germany	PCR	780	17 (2.2)	[69]	

CF, complement fixation test; ELISA, enzyme-linked immunosorbent assay; IF, immunofluorescence test; PCR, polymerase chain reaction.

of study. To estimate the overall proportion of CAP caused by *C. psittaci* infections, random-effects meta-analysis for proportions was performed using ‘metaprop_one’ package in Stata version 13, with Freeman–Tukey transformation to stabilise variances, weighting by study size, stratified by type of laboratory diagnosis [12].

RESULTS

The literature search yielded 147 studies that seemed eligible for full-text review (Fig. 1). During full text review, a total of 90 articles was excluded because the full text could not be found ($n = 10$) or provided no information on *C. psittaci* ($n = 49$), or was not a CAP-aetiological study ($n = 5$) or provided no original data ($n = 10$) or the *Chlamydia* spp. was not specified ($n = 16$). This resulted in the inclusion of 57 relevant studies, with a proportion of CAP caused by *C. psittaci*, ranging from 0 to 6.7% (Table 1). Based on the meta-analysis, *C. psittaci* was the causative pathogen in 1.03% (95% CI 0.79–1.30) of all cases with CAP that were tested for *C. psittaci* infection in these 57 studies (Fig. 2).

There are clear changes over time in diagnostic methods used, and in proportion of CAP reported to be caused by *C. psittaci*. The older studies, including those that were done before 1986, but published from 1986 onwards, were mostly based on complement fixation tests (CF) and reported the highest

proportions, with the largest variability between studies (Figs 2 and 3). CF was used in 23 of the included studies but seems to have been replaced by (micro) immunofluorescence (MIF/IF) as the serological test of choice in more recent CAP-aetiological studies. PCR was used in only four of the later studies. Based on PCR results reported in these four studies only, the reported incidence of *C. psittaci* in CAP is 1.8%. For this PCR-based estimate, only PCR outcomes of the studies were used and CF or IF outcomes that were reported in two of these four studies (classified as ‘mixed or other’ in Figs 2 and 3) were ignored.

DISCUSSION

This review shows that approximately 1% of annual CAP is caused by *C. psittaci* infection. The estimated proportion of *C. psittaci* in CAP was remarkably uniform across the wide variety of studies included in this review and meta-analysis. The group of studies using CF formed an exception, with high variability in the reported proportions, and generally higher proportions of positives. This may be explained by cross-reactivity, for instance with *C. pneumoniae*. Also, some of the included studies were restricted to certain age groups (e.g. children) or patient groups (e.g. intensive care patients), making pooling of the data problematic. Therefore, we repeated the meta-analysis with tighter inclusion criteria, excluding all studies that used only




Fig. 2. Forest plot of meta-analysis of the proportion of CAP caused by *Chlamydia psittaci* infections, stratified by type of laboratory diagnosis.

CF ($n = 20$), all studies in children or intensive care patients ($n = 7$, of which 1 with CF), and all studies with an onset before 1986 (1 used IF, the others used CF). In this meta-analysis with tighter inclusion criteria, the estimated overall proportion remained approximately 1% (presented in online

Supplementary Fig. S1). Another limitation of the present review and meta-analysis is that atypical causative agents in CAP including *C. psittaci* have been shown to be associated with the non-respiratory season (i.e. late spring, summer, and early autumn in Europe), age <60 years, and male gender [70], and contact with




Fig. 3. Proportion of CAP caused by *Chlamydia psittaci* in different studies over time and by type of laboratory diagnosis (top panel), and contribution of each type of laboratory diagnosis to the total over time (bottom panel). In the top panel, each symbol represents a study and the according percentage of CAP patients in which *C. psittaci* was found. The varying colours indicate the diagnostic methods that were used. CF, complement fixation test; IF, immunofluorescence test; 'unsp.', unspecified; PCR, polymerase chain reaction. In the bottom panel, the filled colours represent the contribution of each type of laboratory diagnosis to the total over time, expressed in percentages. 'Year of study' represents the year in which the gathering of data commenced. Although studies published before 1986 were not included, the period in which patient data had been gathered usually differed from the year of publication.

birds. Unfortunately, there was insufficient information for season-, age-, and gender-specific estimates. The risk of exposure to *C. psittaci* is likely to differ across geographical areas. Included studies originated from

multiple countries, mostly in Europe, and particularly Spain ($n = 15$). Nevertheless, the heterogeneity across studies was remarkably low, and the estimate of approximately 1% of CAP being caused by *C. psittaci*

was remarkably robust, given the large variation between the studies regarding geographical location, season, diagnostic tests, study population, and the varying (and often not reported) case definitions for CAP and *C. psittaci* infection.

CAP is a very common condition in all countries of the world. For example, in the Netherlands during the years 2008–2011, the mean annual number of CAP episodes treated in hospitals was 48 843 [71]. Based on the present review one would expect an annual number of 503 hospitalised CAP patients with psittacosis. If based on the four studies using PCR only, of which three originate from the Netherlands, one would expect an annual number of 879 hospitalised CAP patients with psittacosis. The national infectious diseases surveillance system showed only 93 notified psittacosis patients on average per year over the period 2008–2011, including non-hospitalised cases. The estimation based on the present review therefore entails an incidence of psittacosis that is at least five times higher than the reported figure in the Netherlands.

In many countries, including the Netherlands, most CAP patients are managed in primary care [72]. However, the CAP-aetiological studies included in the current review were almost entirely done among hospitalised patients. The importance of psittacosis among pneumonia patients in primary care therefore remains elusive, as the proportion of *C. psittaci* may be different from hospitalised pneumonia patients [33]. Furthermore, although CAP is likely to be the most important clinical presentation of an infection with *C. psittaci*, it is not the only one [1, 73]. Other clinical presentations are also possible upon infection with *C. psittaci*, including severe presentations such as sepsis [4]. Follow-up studies on the burden of psittacosis, that may use the results of our meta-analysis, would need to take into account other clinical presentations as well.

More frequent testing of CAP patients is recommended to reduce the diagnostic deficit and under-ascertainment. The trend over time in which serological methods are replaced by PCR-based methods is important from a public health point of view as PCR during the acute episode is a very specific method, although less sensitive if the diagnosis is only considered later in the disease episode. Positive samples could be genotyped and matched with animal and environmental samples. Currently, all medical microbiology laboratories in the Netherlands are encouraged to implement PCR-based diagnostics for

psittacosis and to send isolates to one laboratory for genotyping [9]. In time, the increased availability of PCR-based methods and the increased cost-effectiveness of the use of these methods in CAP, particularly in the non-respiratory season, could reduce the diagnostic deficit of CAP, provide better data on the burden of disease from psittacosis, and allow for efficient source detection.

SUPPLEMENTARY MATERIAL

The supplementary material for this article can be found at <https://doi.org/10.1017/S0950268817002060>

ACKNOWLEDGEMENTS

The study was funded by the Ministry of Health, Welfare and Sports and from a grant by the Netherlands Organisation for Health Research and Development (ZonMw) to the Plat4m-2Bt-psittacosis project, project number: 522001002.

AUTHOR'S CONTRIBUTIONS

BB conducted the review initiated and designed by WH and LH. WH and LH provided BB with oversight and guidance during the project. BG performed the meta-analysis. All authors reviewed the manuscript critically and contributed with revisions.

REFERENCES

1. **Beeckman DSA, Vanrompay DCG.** Zoonotic *Chlamydophila psittaci* infections from a clinical perspective. *Clinical Microbiology and Infection* 2009; **15**: 11–17.
2. **Halsby KD, et al.** Healthy animals, healthy people: zoonosis risk from animal contact in pet shops, a systematic review of the literature. *PLoS ONE* 2014; **9**: e89309.
3. **Heddema ER, et al.** An outbreak of psittacosis due to *Chlamydophila psittaci* genotype A in a veterinary teaching hospital. *Journal of Medical Microbiology* 2006; **55**: 1571–1575.
4. **Belchior E, et al.** Psittacosis outbreak after participation in a bird fair, Western France, December 2008. *Epidemiology and Infection* 2011; **139**: 1637–1641.
5. **Laroucau K, et al.** Outbreak of psittacosis in a group of women exposed to *Chlamydia psittaci*-infected chickens. *Eurosurveillance* 2015; **20**: pii=21155.
6. **Dickx V, et al.** *Chlamydophila psittaci* zoonotic risk assessment in a chicken and Turkey slaughterhouse. *Journal of Clinical Microbiology* 2010; **48**: 3244–3250.
7. **Vorimore F, et al.** *Chlamydia psittaci* in ducks: a hidden health risk for poultry workers. *Pathogens and Disease* 2015; **73**: 1–9.

8. **van der Hoek W, et al.** Extent of the psittacosis problem in humans: the importance of reliable diagnostics [in Dutch]. *Infectieziekten Bulletin* 2014; **25**: 45–48.
9. **Heddema ER, et al.** Typing of *Chlamydia psittaci* to monitor epidemiology of psittacosis and aid disease control in the Netherlands, 2008 to 2013. *Eurosurveillance* 2015; **20**: pii=21026.
10. **Grayston JT, et al.** A new *Chlamydia psittaci* strain, TWAR, isolated in acute respiratory tract infections. *New England Journal of Medicine* 1986; **315**: 161–168.
11. **Moher D, et al.** Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Medicine* 2009; **6**: e1000097.
12. **Nyaga VN, Arbyn M, Aerts M.** Metaprop: a Stata command to perform meta-analysis of binomial data. *Archives of Public Health* 2014; **72**: 39.
13. **Krech T, et al.** Etiology of atypical pneumonias: a serological study on 1494 patients [in German]. *Schweizerische Medizinische Wochenschrift* 1986; **116**: 2–7.
14. **Jokinen C, et al.** Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. *Clinical Infectious Diseases* 2001; **32**: 1141–1154.
15. **Claesson BA, et al.** Etiology of community-acquired pneumonia in children based on antibody responses to bacterial and viral antigens. *Pediatric Infectious Disease Journal* 1989; **8**: 856–862.
16. **Harrison BDW, et al.** Community-acquired pneumonia in adults in British hospitals in 1982–1983: a survey of aetiology, mortality, prognostic factors and outcome. *Quarterly Journal of Medicine* 1987; **62**: 195–220.
17. **Burman LÅ, et al.** Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, and serology with special reference to antibodies against pneumococcal antigens. *Journal of Infectious Diseases* 1991; **163**: 1087–1093.
18. **Mohamed ARE, Price Evans DA.** The spectrum of pneumonia in 1983 at the Riyadh Armed Forces Hospital. *Journal of Infection* 1987; **14**: 31–37.
19. **Ausina V, et al.** Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain. *European Journal of Clinical Microbiology & Infectious Diseases* 1988; **7**: 343–347.
20. **Blanquer J, et al.** Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study. *Thorax* 1991; **46**: 508–511.
21. **Mensa J, et al.** Treatment of atypical pneumonia with josamycin [in Spanish]. *Medicina Clínica* 1989; **92**: 285–287.
22. **Ekman MR, et al.** Evaluation of serological methods in the diagnosis of *Chlamydia pneumoniae* pneumonia during an epidemic in Finland. *European Journal of Clinical Microbiology & Infectious Diseases* 1993; **12**: 756–760.
23. **Örtqvist A, et al.** Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. *European Respiratory Journal* 1990; **3**: 1105–1113.
24. **Lim WS, et al.** Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. *Thorax* 2001; **56**: 296–301.
25. **Aderaye G.** Community acquired pneumonia in adults in Addis Ababa: etiologic agents and the impact of HIV infection. *Tubercle and Lung Disease* 1994; **75**: 308–312.
26. **Moine P, et al.** Severe community-acquired pneumonia: etiology, epidemiology, and prognosis factors. *Chest* 1994; **105**: 1487–1495.
27. **Almirall J, et al.** Differences in the etiology of community-acquired pneumonia according to site of care: a population-based study. *Respiratory Medicine* 2007; **101**: 2168–2175.
28. **Ouchi K, et al.** Prevalence of *chlamydia pneumoniae* in acute lower respiratory infection in the pediatric population in Japan. *Acta Paediatrica Japonica* 1994; **36**: 256–260.
29. **Torzillo P, et al.** Etiology of acute lower respiratory tract infection in Central Australian Aboriginal children. *Pediatric Infectious Disease Journal* 1999; **18**: 714–721.
30. **The Nordic Atypical Pneumonia Study Group.** Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. *Journal of Antimicrobial Chemotherapy* 1997; **39**: 499–508.
31. **Barnes DJ, et al.** The role of viruses and atypical organisms in the pathogenesis of adult pneumonia in Papua New Guinea. *Papua New Guinea Medical Journal* 1991; **34**: 13–16.
32. **Dumouchelle MW, Smith KK, Qadri SMH.** Respiratory tract infections at a tertiary care centre: a seroepidemiological survey. *Medical Science Research* 1992; **20**: 797–798.
33. **Michetti G, et al.** Community-acquired pneumonia: is there difference in etiology between hospitalized and out-patients? *Minerva Medica* 1995; **86**: 341–351.
34. **Marrie TJ, et al.** Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. *American Journal of Medicine* 1996; **101**: 508–515.
35. **Pareja A, et al.** Etiologic study of patients with community-acquired pneumonia. *Chest* 1992; **101**: 1207–1210.
36. **Sillis M, et al.** The differentiation of *Chlamydia* species by antigen detection in sputum specimens from patients with community-acquired acute respiratory infections. *Journal of Infection* 1992; **25**: 77–86.
37. **Mlinaric-Galinovic G, et al.** Etiology of atypical pneumonia in children and adults. *Paediatrica Croatica* 1995; **39**: 247–251.
38. **Gendrel D, et al.** Etiology and response to antibiotic therapy of pneumonia in French children. *European Journal of Clinical Microbiology & Infectious Diseases* 1997; **16**: 388–391.
39. **Ishida T, et al.** Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan. *Chest* 1998; **114**: 1588–1593.
40. **Rosón B, et al.** Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired

- pneumonia in patients hospitalized on the basis of conventional admission criteria. *Clinical Infectious Diseases* 2001; **33**: 158–165.
41. **Paganin F, et al.** Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. *European Respiratory Journal* 2004; **24**: 779–785.
 42. **Fernández-Sabé N, et al.** Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. *Medicine (Baltimore)* 2013; **82**: 159–169.
 43. **García-Vidal C, et al.** Aetiology of, and risk factors for, recurrent community-acquired pneumonia. *Clinical Microbiology and Infection* 2009; **15**: 1033–1038.
 44. **Ruiz M, et al.** Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. *American Journal of Respiratory and Critical Care Medicine* 1999; **160**: 397–405.
 45. **Socan M, et al.** Microbial aetiology of community-acquired pneumonia in hospitalised patients. *European Journal of Clinical Microbiology & Infectious Diseases* 1999; **18**: 777–782.
 46. **Tong CYW, et al.** Multiplex polymerase chain reaction for the simultaneous detection of *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Chlamydia psittaci* in respiratory samples. *Journal of Clinical Pathology* 1999; **52**: 257–263.
 47. **Gutiérrez FJA, et al.** Prospective study of 221 community acquired pneumonias followed up in an outpatient clinic: etiology and clinical-radiological progression [in Spanish]. *Medicina Clínica (Barcelona)* 2001; **116**: 161–166.
 48. **Luna CM, et al.** Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. *Chest* 2000; **118**: 1344–1354.
 49. **Falguera M, et al.** Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity. *Archives of Internal Medicine* 2001; **161**: 1866–1872.
 50. **Saito A, et al.** Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. *Journal of Infection and Chemotherapy* 2006; **12**: 63–69.
 51. **Beović B, et al.** Aetiology and clinical presentation of mild community-acquired bacterial pneumonia. *European Journal of Clinical Microbiology & Infectious Diseases* 2003; **22**: 584–591.
 52. **Gutiérrez F, et al.** Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. *European Journal of Clinical Microbiology & Infectious Diseases* 2005; **24**: 377–383.
 53. **Strålin K, et al.** Definite, probable, and possible bacterial aetiologies of community-acquired pneumonia at different CRB-65 scores. *Scandinavian Journal of Infectious Diseases* 2010; **42**: 426–434.
 54. **Kuzman I, et al.** Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study. *Journal of Chemotherapy* 2005; **17**: 636–642.
 55. **Briones ML, et al.** Assessment of analysis of urinary pneumococcal antigen by immunochromatography for etiologic diagnosis of community-acquired pneumonia in adults. *Clinical and Vaccine Immunology* 2006; **13**: 1092–1097.
 56. **Sohn JW, et al.** Atypical pathogens as etiologic agents in hospitalized patients with community-acquired pneumonia in Korea: a prospective multi-center study. *Journal of Korean Medical Science* 2006; **21**: 602–607.
 57. **Ishida T, et al.** A 3-year prospective study of a urinary antigen-detection test for *Streptococcus pneumoniae* in community-acquired pneumonia: utility and clinical impact on the reported etiology. *Journal of Infection and Chemotherapy* 2004; **10**: 359–363.
 58. **Ewig S, et al.** Factors associated with unknown aetiology in patients with community-acquired pneumonia. *European Respiratory Journal* 2002; **20**: 1254–1262.
 59. **Ishiguro T, et al.** Etiology and factors contributing to the severity and mortality of community-acquired pneumonia. *Internal Medicine* 2012; **52**: 317–324.
 60. **Díaz A, et al.** Etiology of community-acquired pneumonia in hospitalized patients in Chile: the increasing prevalence of respiratory viruses among classic pathogens. *Chest* 2007; **131**: 779–787.
 61. **Charles PGP, et al.** The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. *Clinical Infectious Diseases* 2008; **46**: 1513–1521.
 62. **Walden AP, et al.** Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. *Critical Care* 2014; **18**: 1–9.
 63. **Miyashita N, et al.** Clinical features and the role of atypical pathogens in nursing and healthcare-associated pneumonia (NHCA): differences between a teaching university hospital and a community hospital. *Internal Medicine* 2012; **51**: 585–594.
 64. **Bütün Y, et al.** *Chlamydia* and *Mycoplasma* serology in respiratory tract infections of children. *Tüberküloz ve Toraks Dergisi* 2006; **54**: 254–258.
 65. **Capelastegui A, et al.** Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. *BMC Infectious Diseases* 2012; **12**: 134.
 66. **Spoorenberg SMC, et al.** *Chlamydia psittaci*: a relevant cause of community-acquired pneumonia in two Dutch Hospitals. *Netherlands Journal of Medicine* 2016; **74**: 75–81.
 67. **van Gageldonk-Lafeber AB, et al.** The aetiology of community-acquired pneumonia and implications for patient management. *Netherlands Journal of Medicine* 2013; **71**: 418–425.
 68. **Huijskens EGW, et al.** Viral and bacterial aetiology of community-acquired pneumonia in adults. *Influenza and Other Respiratory Viruses* 2012; **7**: 567–573.
 69. **Dumke R, et al.** *Mycoplasma pneumoniae* and *Chlamydia* spp. infection in community-acquired pneumonia, Germany, 2011–2012. *Emerging Infectious Diseases* 2015; **21**: 426–433.

70. **Raeven VM, et al.** Atypical aetiology in patients hospitalised with community-acquired pneumonia is associated with age, gender and season; a data-analysis on four Dutch cohorts. *BMC Infectious Diseases* 2016; **16**: 299.
71. **Rozenbaum MH, et al.** Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: a nationwide retrospective claims database analysis. *Vaccine* 2015; **33**: 3193–3199.
72. **Snijders B, et al.** General practitioners' contribution to the management of community-acquired pneumonia in the Netherlands: a retrospective analysis of primary care, hospital, and national mortality databases with individual data linkage. *Primary Care Respiratory Journal* 2013; **22**: 400–405.
73. **Cunha BA.** The atypical pneumonias: clinical diagnosis and importance. *Clinical Microbiology and Infection* 2006; **12**(Suppl 3): 12–24.